Ligand Pharmaceuticals Incorporated
LGND · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $72 | $23 | $45 | $20 |
| Short-Term Investments | $184 | $147 | $167 | $322 |
| Receivables | $42 | $39 | $35 | $92 |
| Inventory | $14 | $24 | $13 | $27 |
| Other Curr. Assets | $19 | $4 | $3 | $5 |
| Total Curr. Assets | $332 | $237 | $264 | $465 |
| Property Plant & Equip (Net) | $25 | $25 | $27 | $33 |
| Goodwill | $105 | $103 | $106 | $106 |
| Intangibles | $267 | $300 | $353 | $387 |
| Long-Term Investments | $11 | $112 | $3 | $0 |
| Tax Assets | $0 | $0 | $9 | $36 |
| Other NC Assets | $203 | $10 | $2 | $272 |
| Total NC Assets | $610 | $550 | $499 | $833 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $942 | $787 | $763 | $1,298 |
| Liabilities | – | – | – | – |
| Payables | $5 | $2 | $5 | $8 |
| Short-Term Debt | $1 | $0 | $77 | $1 |
| Tax Payable | $1 | $0 | $0 | $0 |
| Deferred Revenue | $2 | $2 | $1 | $1 |
| Other Curr. Liab. | $27 | $12 | $15 | $31 |
| Total Curr. Liab. | $37 | $17 | $99 | $42 |
| LT Debt | $6 | $6 | $10 | $323 |
| Deferred Rev, NC | $0 | $15 | $0 | $0 |
| Deferred Tax Liab, NC | $33 | $32 | $31 | $31 |
| Other NC Liab. | $36 | $17 | $25 | $81 |
| Total NC Liab. | $74 | $70 | $66 | $435 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $7 | $6 | $11 | $4 |
| Total Liabilities | $111 | $86 | $165 | $476 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | $499 | $503 | $451 | $449 |
| AOCI | -$6 | -$1 | -$1 | -$1 |
| Other Equity | $337 | $199 | $148 | $373 |
| Total Equity | $830 | $701 | $597 | $821 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $942 | $787 | $763 | $1,298 |
| Net Debt | -$65 | -$17 | $43 | $305 |